Cargando…

Sotrovimab: is it effective in early treatment of mild and moderate COVID-19 infections? A retrospective study

BACKGROUND: The monoclonal antibody sotrovimab is manufactured to antagonize many types of coronaviruses including the SARS-CoV-2. It is used mainly to treat mild and moderate COVID-19 infection and to prevent the progression of the disease from critical disease to severe. OBJECTIVES: To assess the...

Descripción completa

Detalles Bibliográficos
Autor principal:	Elesdoudy, Ahmed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8685821/ http://dx.doi.org/10.1186/s43168-021-00104-8

Ejemplares similares

Population pharmacokinetics and exposure‐response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID‐19
por: Sager, Jennifer E., et al.
Publicado: (2023)

EE465 Cost-Effectiveness of Sotrovimab for the Treatment of Mild-to-Moderate COVID-19 in Patients at High Risk of Disease Progression in Italy
por: Piccolo, F, et al.
Publicado: (2022)

Sotrovimab for COVID-19
Publicado: (2021)

1150. Resistance Analysis in the COMET-TAIL Study: Participants with Mild-to-Moderate COVID-19 Treated with Intramuscular or Intravenous Sotrovimab
por: Agostini, Maria L, et al.
Publicado: (2022)

1145. Real-world Effectiveness of Sotrovimab for the Early Treatment of COVID-19 in the US
por: Cheng, Mindy M, et al.
Publicado: (2022)

1154. Safety, Tolerability, and Viral Pharmacodynamics of the IgG Monoclonal Antibody Sotrovimab Administered via Intramuscular Injection for the Treatment of Early Mild-to-Moderate COVID-19
por: Gupta, Anil K, et al.
Publicado: (2022)

Safety, Virology, Pharmacokinetics, and Clinical Experience of High-Dose Intravenous Sotrovimab for the Treatment of Mild to Moderate COVID-19: An Open-Label Clinical Trial
por: Moya, Jaynier, et al.
Publicado: (2023)

Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar
por: Zaqout, Ahmed, et al.
Publicado: (2022)

Use of Sotrovimab in a Pregnant Patient With COVID-19 Infection
por: Gupta, Isha, et al.
Publicado: (2022)

Clinical Outcomes of Sotrovimab Treatment in 10 High-Risk Patients with Mild COVID-19: A Case Series
por: Takeda, Kenichiro, et al.
Publicado: (2022)

518. Comparable Outcomes of Remdesivir and Sotrovimab among High-risk Patients with Mild to Moderate COVID-19 During the Omicron BA.1 Surge
por: Chesdachai, Supavit, et al.
Publicado: (2023)

Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S COCOPREV study)
por: Martin-Blondel, Guillaume, et al.
Publicado: (2022)

Early treatment with sotrovimab monoclonal antibody in kidney transplant recipients with Omicron infection
por: Chavarot, Nathalie, et al.
Publicado: (2022)

502. Early COVID-19 Treatment with SARS-CoV-2 Neutralizing Antibody Sotrovimab
por: Gupta, Anil K, et al.
Publicado: (2021)

Endocrine, metabolic, and hepatic dysfunction in patients with COVID-19 pneumonia with severe and critically ill status
por: Elesdoudy, Ahmed
Publicado: (2022)

Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019
por: Razonable, Raymund R., et al.
Publicado: (2022)

Time to negative PCR conversion amongst high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated with sotrovimab or nirmatrelvir
por: Martin-Blondel, Guillaume, et al.
Publicado: (2023)

Sotrovimab: First Approval
por: Heo, Young-A
Publicado: (2022)

Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the USA
por: Cheng, Mindy M., et al.
Publicado: (2023)

Clinical Effectiveness of Regdanvimab Treatment for Mild-to-Moderate COVID-19: A Retrospective Cohort Study
por: Jang, Young Rock, et al.
Publicado: (2022)

Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2
por: Martin-Blondel, Guillaume, et al.
Publicado: (2022)

Assessment of symptoms in COMET-ICE, a phase 2/3 study of sotrovimab for early treatment of non-hospitalized patients with COVID-19
por: Satram, Sacha, et al.
Publicado: (2023)

Experience with sotrovimab treatment of SARS‐CoV‐2‐infected patients in Denmark
por: Rasmussen, Line Dahlerup, et al.
Publicado: (2023)

Treatment of persistent COVID-19 in two B-cell-depleted patients with the monoclonal antibody Sotrovimab
por: Totschnig, David, et al.
Publicado: (2022)

Sotrovimab Treatment for COVID-19 Effective in a B-Cell-Depleted Patient After Anti-CD20 Treatment
por: Murase, Kazuyuki, et al.
Publicado: (2023)

CO103 Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the National COVID Cohort Collaborative (N3C)
por: Bell, C., et al.
Publicado: (2023)

Lack of efficacy for sotrovimab use in patients with COVID-19: A meta-analysis
por: Ao, Guangyu, et al.
Publicado: (2022)

Real-world Experience of Sotrovimab in High-risk, Immunocompromised COVID-19 Patients
por: Birk, Navina K, et al.
Publicado: (2022)

Sotrovimab use in Japanese inpatients with COVID-19: post-infusion adverse events
por: Yoshida, Junichi, et al.
Publicado: (2022)

Azithromycin for mild-to-moderate COVID-19
por: Patel, Jigar, et al.
Publicado: (2021)

Effectiveness of Sotrovimab in the Omicron Storm Time: A Case Series
por: Cicchitto, Gaetano, et al.
Publicado: (2022)

LB1577. Outcomes of Pregnant Women Exposed to Sotrovimab for the Treatment of COVID-19 in the Omicron Predominant Era (PRESTO)
por: Tuan, Jessica, et al.
Publicado: (2022)

Outcomes of pregnant women exposed to Sotrovimab for the treatment of COVID-19 in the BA.1 Omicron predominant era (PRESTO)
por: Tuan, Jessica J., et al.
Publicado: (2023)

Effectiveness and Safety of Regdanvimab in Patients With Mild-To-Moderate COVID-19: A Retrospective Cohort Study
por: Park, Susin, et al.
Publicado: (2022)

Sotrovimab in pediatric cardiac transplant recipients with SARS-CoV2 infection
por: Weber, Sven C., et al.
Publicado: (2022)

Sotrovimab: Emergence of acquired resistance: 4 case reports
Publicado: (2022)

A naturopathic treatment approach for mild and moderate COVID-19: A retrospective chart review
por: Barber, Melissa S., et al.
Publicado: (2021)

Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study
por: Evans, Andrew, et al.
Publicado: (2023)

The importance of early detection of ENT symptoms in mild-to-moderate COVID-19
por: Spinato, Giacomo, et al.
Publicado: (2021)

Sotrovimab in Hospitalized Patients with SARS-CoV-2 Omicron Variant Infection: a Propensity Score-Matched Retrospective Cohort Study
por: Woo, Marcel S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a0pk2m089e5mt952vh7ktcb4tv